Previous studies have suggested that the blocking IL8-CXCR2 pathway might have a therapeutic potential in a variety of tumours24–27 including AML and myelodysplastic syndromes (MDS)28. This evidence concerns the gene CXCR2 and acute myeloid leukemia.